



Era7 launches its new service Genome7: An integrated solution for Cancer Genomics

Biospain 2014. Santiago de Compostela, 24th September 2014

Era7 announces today the launch of Genome7 (www.genome7.com), a new service for Cancer Genomics projects that offers its clients an integrated and expert solution. The radical revolution that is experimenting Human Genomics is changing the way we understand and study pathologies. In fact, it is one of the pillars of what is known as Personalised Medicine, thanks to which in the future the processes of diagnostics, treatment, prediction and prevention in the population of patients with a pathology will be specific for every one of them, being able to adapt each case to their molecular peculiarities.

There is no doubt that one of the main pathologies today is cancer and it is a fact that Cancer Genomics is shaping the way tumours are diagnosed, classified and treated. "Genome7 will offer its clients high-quality integrated Cancer Genomics Data in an interactive web application, easy-to-use and with access to the best databases, making the interpretation of the results much easier" declared Dr. Eduardo Pareja, CEO of Era7 and responsible of the new line of business. He added: "With Genome7 we want to facilitate the analysis of the specific mutations in a tumor sample in the context of biological networks". Sometimes mutations in tumours of the same type converge in the sense that they affect the same biological network, whether it be signalling, transcription or metabolic. "Our successful project Bio4j, a Big Data bioinformatics platform that this summer has been selected by Google for its project Google Summer of Code, will allow us to offer an innovative way of visualising the results of the exomes, genomes and RNA-seq of the tumor samples".

Offering this new and ambitious service has been made possible by the experience of over 6 years Era7 has in Next Generation Sequencing, Genomics and Cloud

Computing and the collaboration of Rafer, which has recently become Era7 Bioinformatics' partner and will distribute exclusively this service world-wide.

About Era7 Bioinformatics

Era7 Bioinformatics (www.era7bioinformatics.com) is a leader company in Next Generation Sequencing (NGS) and Bioinformatics for Bacterial Genomics and Metagenomics. Era7 was founded in Spain and it has a subsidiary in Cambridge, Massachusetts, USA since 2012. Era7's business model is based on helping its clients in all the steps of a genomics project, from the design of the project and the sequencing, to an expert bioinformatics analysis, specialised bioinformatics consultancy and the development of applications and customised software. This is possible thanks to the strong research-oriented activity that Era7 carries out, the use of Cloud Computing and the advantages of developing software under an Open Source model.

About Genome7

Genome7 (www.genome7.com) is a business line of Era7 that offers high quality integrated services on Cancer Genomics. Under the traditional Era7's model of helping in all the steps of the project (experimental design, sequencing, data analysis, interpretation, consultancy, support, data storage and customised software development), Genome7 offers services that integrate exome, genome, RNA-seq, miRNA and lncRNA so that researchers and clinicians can gain the highest value from their Cancer Genomics projects.

Contact information:

Dr. Eduardo Pareja

CEO of Era7

info@era7.com

34 958 256771